Method for determining individual's blood glucose concentration

FIELD: medicine.

SUBSTANCE: invention refers to medicine. Determining an individual's blood glucose concentration is ensured by measuring high-frequency and low-frequency body region impedances successfully at pre-set intervals of time with using spaced electrodes fixed on the body. The measured high-frequency impedance provides the basis to determine a fluid volume in the body tissues between the electrodes, while the measured low-frequency impedance is used to determine an extracellular fluid volume in the body tissues between the electrodes. That is followed by deriving a metabolic component increment of the above extracellular fluid volume formed by the body energy carrier synthesis and recovery by calculating an increment of the above measured fluid volume in the body tissues between the electrodes as compared to the previous measured value, calculating a difference of the above increment of the fluid volume in the body tissues between the electrodes and the above increment of the extracellular fluid volume in the body tissues between the electrodes. A blood glucose increment is measured by standardising the above metabolic component increment of the extracellular fluid volume, while the individual's blood glucose concentration is determined by summing up the above glucose concentration increment and the blood glucose concentration derived at the previous stage of measurements. The glucose concentration at the first interval of time is determined by summing up the above blood glucose increment derived at the first interval of time and the initial glucose concentration.

EFFECT: method enables continuous and non-invasive high-accuracy determination of the individual's blood glucose concentration.

5 cl, 6 dwg, 3 ex

 

The technical FIELD

The invention relates to methods of medical examination of person non-surgical methods, namely the determination of glucose concentration in human blood based on the measurement of electrical resistance of the body.

The LEVEL of TECHNOLOGY

Known non-invasive methods of measuring the concentration of glucose in human blood, is based on measuring the electrical resistance (impedance) of the part of the body or components of the impedance.

For example, there is a method of indicating the sugar content in the blood [patent RU 2073242, G01N 33/4, 1997], in which the level of glucose in the blood of the patient is measured by changing the dielectric constant of the finger placed in the electric field of the Converter.

There is also known a method of controlling the amount of sugar in the blood [patent RU 2088927, G01N 33/49, 1997], in which the measurement is produced by changing the reactance oscillator circuits included in the secondary circuit of the high-frequency generator, by the direct impact of man on the elements of the oscillating circuits. Thus, the amount of sugar in the blood was determined by the change in current in the secondary circuit of the high-frequency generator.

The known method [patent US 5792668, G01N 27/00, 1998], which carried out the spectral analysis of the reflected from the body of the person the century or through high-frequency radiation. The measured parameter is the phase shift between the incident and reflected or passed by the waves, which characterizes the reactive component of the resistance body. On the measured parameters of the phase spectrum is judged on the concentration in the blood of substances, in particular glucose concentration.

There is a method implemented by the device described in the certificate of utility model RU 9703, AV 5/00, 1999. In this device, the measurement of glucose concentration in blood based on measuring the impedance of the human body section at two frequencies, determining the capacitive component of the resistance of the human body and converting the obtained value of the capacitive component in the value of glucose concentration in the patient's blood.

There is a method of measuring the concentration of glucose in the blood is a non-invasive method [patent US 6517482, AV 5/00, 2003]. The method is based on measuring the resistance between two electrodes on multiple frequencies and subsequent determination of glucose concentration based on the measured values.

There is a method of determining the concentration of glucose in the blood is a non-invasive method by measuring the electrical transfer functions by means of two pairs of four-electrode sensors [patent RU 2342071, AV 5/053, 2008]. The concentration of glucose in the blood is determined by a predetermined mathematical model.

There is also known a method of determining the concentration of glucose in blood [US patent 7050847, AV 5/00, 2006], which measure the impedance of the section of the human body using sensors at different frequencies. At high frequencies the impedance value related to the amount of fluid in the tissues of the body, and at low frequencies with the volume of extracellular fluid. For measured values determine the parameters of biological fluids in the body, they will judge the concentration of glucose in the blood.

However, the methods have a common drawback: the resulting estimate of glucose concentration in human blood is considerably inferior to the accuracy of the measurements carried out direct - invasive methods. At the same time invasive methods that require the taking of blood samples, is clearly inferior to the non-invasive from the point of view of comfort and security.

The technical problem to be solved by the present invention is directed, is the creation of a non-invasive method for continuous determination of glucose concentration in human blood with a higher accuracy compared to known non-invasive methods.

DISCLOSURE of INVENTIONS

The inventive method of determining the concentration of glucose in the blood characterized by the fact that sequentially at set time intervals:

measured values of the impedance plot of the human body in the high frequency and low frequency using a fixed on the body and spaced from each other electrode,

on the basis of measured values of impedance at high frequency gain estimate of the volume of liquid contained in the tissues of the human body section between the electrodes,

on the basis of measured values of impedance at low frequency gain estimate of the volume of extracellular fluid contained in the tissues of the human body section between the electrodes,

then define the increment value of the metabolic component of the above-mentioned volume of the extracellular fluid associated with the synthesis and utilization of energy in the human body, by determining the increment referred to estimates of the volume of liquid contained in the tissues of the human body section between the electrodes, compared with the previous measurement, determine the increment referred to estimating the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes, compared with the previous measurement, and then calculating the difference between the increment estimates of the volume of liquid contained in the tissues of the human body section between the electrodes, and the above-mentioned increment estimates of the volume of extracellular fluid contained in the tissues of the human body section between the electrodes,

determine the increment value of glucose concentration in human blood by normalizing the above variables mentioned increment metabolic components that are contributing to the overall volume of the extracellular fluid,

as the concentration of glucose in the blood is determined by summing the above variables increment of glucose concentration with a value of the concentration of glucose in the blood determined in the previous step measurements,

the glucose concentration at the first time interval is determined by summing the above-mentioned increment of glucose concentration in human blood obtained at the first time interval, the initial value of the glucose concentration.

The physical basis of the method is to measure the volume of the liquid part of the body of man. Water in the human body is 70% of its weight. However, it does not form a single space, and distributed in body tissues. The boundary of the fluid are the walls of blood vessels and cell membranes, which consist of all body tissues. It is customary to distinguish between three water: intracellular fluid, intravascular fluid (liquid blood plasma and extracellular fluid (the fluid that fills the intercellular space).

Intracellular fluid or liquid contained inside the cells, tissues and red blood cells, approximately 30-40% of the mass of the body.

Intravascular and interstitial fluid form the extracellular fluid space, which constitute about 20% of the mass of the body.

In each of these is of alcosta present matter, designed to maintain the life of the cells or their waste products to be removed or processing inside the body. These substances during the life of the body move through the cell membrane from one space to another. One of the driving forces behind this migration is the osmotic pressure, which depends on the gradient of concentration of substances across the membrane.

At rest there is a dynamic equilibrium of metabolic processes in the body. The emergence of a concentration gradient of osmotic pressure, for example, supply of glucose from the gastrointestinal tract after ingestion causes water to move through the cell membrane in the direction of the space with a higher concentration of dissolved substances. The volume of water sectors change. But then included regulatory mechanisms that seek to restore the disturbed balance between these spaces. That is, the change in the amount of water the body has a characteristic (cyclic) features. These features can be used as an indicator of the nature of metabolic processes in the body, such as an increase in the concentration of glucose in the blood after a meal.

The basis of the method consists in forming the estimate of the increase or is menichini concentration of glucose in the blood on the dynamics of the volume of its waters, which is examined during periodic measurement values of the impedance of the human body section.

In private cases, the implementation of the method perform the following operations.

At the beginning of the measurements is to determine the initial values of the concentration of glucose in the blood, which produces another alternative method, non-invasive or invasive. This is the absolute value individually for each person and determines not only the nature of dynamics of change of glucose concentration, but its absolute values in different periods of human activity.

In particular, for measuring the impedance of the human body section can be used at least two electrodes are installed at some distance from each other, preferably to set the electrodes on the peripheral parts of the body, such as the hand or finger.

Impedance measurements of the human body section at high and low frequencies are produced with the time interval from 1 second to 10 minutes, while for ease of hardware implementation of the method, the time intervals chosen are the same.

Additionally, during the measurement, record the time of the meal, and this fact is used for correction of the dynamics of the receipt of the glucose in the human body.

In particular, when the present method based on the values of the pulse the Anza section of the body, measured at high and low frequencies periodically at time tkdefine the following settings:

1) the volume of liquid contained in the tissues of the human body section between the electrodes Wsum(tk), is determined by the formula:

Wsum(tk)=AL2/ZHF(tk),

where: L is the distance between the electrodes;

ZHF(tk- the value of the impedance of the human body section, measured at the high frequency HF in time;

A calibration factor determined by the formula:

A=Vsum·ZHF/L2,

where: Vsumpre - calculated volume of liquid contained in the tissues of the human body section between the electrodes;

ZHFpre - obtained value of the impedance of the section of the human body at high frequency HF;

2) the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes Wout(tk), is determined by the formula:

Wout(tk)=B·L2/ZLF(tk),

where: ZLF(tk- the value of the impedance of the human body section, edit the extended low frequency LF at time t k.

B - calibration factor determined by the formula:

B=Vout·ZLF/L2;

where: Voutpre - calculated volume of the extracellular fluid contained in the body of a man between the electrodes;

ZLFpre - obtained value of the impedance of the section of the human body at a low frequency LF;

3) the increment value of the metabolic component of the volume of extracellular fluid ΔWosm(tk) is determined by the formula:

ΔWosm(tk)=[Wsum(tk-1)-Wsum(tk)]-Ka[wout(tk-1)-Wout(tk)],

where: Wsum(tk-1) - the volume of liquid contained in the tissues of the human body section between the electrodes, for the previous measurement at time tk-1;

Wout(tk-1) - the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes, for the previous measurement at time tk-1;

Toandis a coefficient that depends on the value of the hematocrit of a person and which is chosen in the range from 1.2 to 2.1;

4) the increment value of glucose concentration in human blood ΔG(tk) is defined as:

ΔG(tk)=ΔWosm(tk)-KE·KPR/Kg,

where: Kgthe normalization factor, which is chosen in the range from 0,005 l2mmol-1to 0.006 l2 mmol-1.

ToE- coefficient depending on the meal, and when the determination of glucose concentration in human blood before a meal is ToEchosen in the range from 0.23 to 0.4, and when the determination of glucose concentration in human blood after a meal is ToEchosen in the range from 0.6 to 1.0;

KPR- the factor used to determine the glucose concentration in the blood within a period of time from 20 minutes to 45 minutes after eating and taking the values "1" or "-1" depending on the sign of the value referred to increment the metabolic component of the volume of the extracellular fluid by the following rule:

KPR=1, if the increment of the metabolic component of the volume of extracellular fluid ΔWosm(tk) is greater than 0,

KPR=-1, if the increment of the metabolic component of the volume of extracellular fluid ΔWosm(tk) is less than 0.

BRIEF DESCRIPTION of DRAWINGS

The invention is illustrated in the following graphics.

Figure 1 shows the results of determining the concentration of glucose in the blood for the first volunteer.

Figure 2 shows the results of determining the concentration of glucose in the blood for a second volunteer.

Figure 3 shows the results of determining the concentration of glucose in the blood for a third volunteer.

the ri on Figa, Figa and Figa the graphs of change of glucose concentration determined in various ways, including the method according to the invention, and Fig.1b, Fig.2b and Fig.3b the graphs of measured values of impedance and temperature.

The IMPLEMENTATION of the INVENTION

The method is as follows.

On the part of the human body fix separated from each other by a distance L two electrodes. The most effective electrodes set on the peripheral parts of the body, for example on the hand, in particular on the forearm or finger. The best result would be achieved if this will be ring electrodes, covering the forearm or finger.

Since the method in accordance with the present invention is based on calculating the increment values of glucose concentration in human blood with subsequent summation of these values, however, before the beginning of measurements of the impedance measure the concentration of glucose in the blood by any other available means of invasive or non-invasive, the value of which is taken for the initial.

Impedance measurement body part of a person between the electrodes of the lead at two frequencies: high frequency HF and low frequency LF. High frequency HF is selected in the range from 200 kHz to 2 MHz, low frequency LF is chosen in the range from 20 kHz to 80 kHz. Measurement of the total electric with the resistance or the components of impedance of a section of human tissue may be one of the known methods, in particular, using radiation of high-frequency and resistance measurements using capacitive sensors. Measure the impedance of the section of the human body through the selected time intervals in the range from 1 to 10 minutes

During the measurements, record the time of the meal, characterizing the flow of glucose into the body from the outside to determine the increment of the metabolic component of the volume of extracellular fluid associated with glucose, taking into account the time elapsed after recorded during the measurement of the moment of the beginning of the meal.

On the basis of the initial values of the concentration of glucose in the blood, the current sequential measurements of the impedance of the human body section at high and low frequencies and considering the time of the next meal the glucose concentration in human blood is determined as follows.

1. On the value of the impedance of the human body section, measured at the high frequency HF at time tk-ZHF(tk), and taking into account the distance L between the electrodes calculate the volume of liquid contained in the tissues of the human body section between the electrodes Wsum(tk):

Wsum(tk)=A·L2/ZHF(tk),

where: A is a calibration factor determined by the formula:

A=Vsum-ZHF/L2.

Here Vsum- pre is sustained fashion the calculated volume of liquid, contained in the tissues of the human body section between the electrodes. This value can be obtained, for example, by calculation on the basis of anatomic correlations selected for impedance measurement body part of a person. To determine the calibration coefficient A is a value of the impedance of the human body section at a high frequency ZHFobtained before the beginning of measurements associated with the determination of glucose concentration in human blood in accordance with the present invention.

2. On the value of the impedance of the human body section, measured at low frequency LF at time tk- ZLF(tk), and taking into account the distance L between the electrodes calculate the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes Wout(tk):

Wout(tk)=B·L2/ZLF(tk),

where: is the calibration factor determined by the formula:

B=Vout, ZLF/L2.

Here Voutpre - calculated volume of the extracellular fluid contained in the body of a man between the electrodes. This value can be obtained, for example, by calculation on the basis of anatomic correlations selected for impedance measurement body part of a person. To determine the calibration ratios are the NTA is used In the impedance value of the part of the human body at a low frequency Z LFobtained before the beginning of measurements associated with the determination of glucose concentration in human blood in accordance with the present invention.

3. Next, the obtained values of the liquid volume contained in the tissues of the human body section between the electrodes, and the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes, is used to calculate the increment of the metabolic component of the volume of extracellular fluid ΔWosm(tk). Using the values of the volume of liquid obtained for impedance measurement at time tkand for the previous measurement at time tk-1. The increment value of the metabolic component of the volume of extracellular fluid is determined by the formula:

ΔWosm(tk)=[Wsum(tk-1)-Wsum(tk)]-Ka[wout(tk-1)-Wout(tk)],

where: Wsum(tk) - the volume of liquid contained in the tissues of the human body section between the electrodes, for the current measurement at time tk;

Wsum(tk-1) - the volume of liquid contained in the tissues of the human body section between the electrodes, for the previous measurement at time tk-1;

Wout(tk) - the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes, the current measurement at time t k;

Wout(tk-1) - the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes, for the previous measurement at time tk-1;

Kais a coefficient that depends on the value of the hematocrit of a person and which is chosen in the range from 1.2 to 2.1.

4. Based on the obtained values of ΔWosm(tk) and considering the time of the meal define the increment value of glucose concentration in human blood:

ΔG(tk)=ΔWosm(tkKE·KPR/Kg,

where: Kgthe normalization factor, which is chosen in the range from 0,005 l2mmol-1to 0.006 l2mmol-1.

ToE- coefficient depending on the meal, and when the determination of glucose concentration in human blood before a meal is ToEchosen in the range from 0.23 to 0.4, and when the determination of glucose concentration in human blood after a meal is ToEchosen in the range from 0.6 to 1.0;

KPR- the factor used to determine the glucose concentration in the blood within a period of time from 20 minutes to 45 minutes after eating and taking the values "1" or "-1" depending on the sign of the value referred to increment the metabolic component of the volume of the extracellular fluid by the following rule:

KPR=1 if womenwearing metabolic component of the volume of extracellular fluid ΔW osm(tk) is greater than 0,

KPR=-1, if the increment of the metabolic component of the volume of extracellular fluid ΔWosm(tk) is less than 0.

5. The total value of glucose concentration in human blood at time tkdetermined as follows:

G(tk)=G0+i=1kΔG(ti),

where: G0- the initial value of glucose concentration in human blood;

ΔG(ti) - the value of all increments of glucose concentration in human blood, obtained from the beginning of the measurements until time tkand i={1,k}.

Thus, knowing the initial value of glucose concentration in human blood G0and producing periodically measuring the impedance of the human body section at high and low frequencies - ZHF(tkand ZLF(tk), you can determine the current value of glucose concentration in human blood. The present invention can be implemented as a relatively simple measuring device with the ability to calculate specified parameters characterizing changed the e volume of water in human tissues, and finally - the current value of glucose concentration in human blood, including taking into account his individual physiological characteristics and moments of the meal.

EXAMPLES

Example 1. The processing of measurement results healthy Volunteers 1.

Male 38 years old, healthy, took the food load in the form of 300 g sweet drink (Pepsi Cola). On Fig.lb shows graphs of the variation of the values of the impedance ZHFand ZLFand temperature T°C, taken from the sensor located on the forearm, and on Figa shows a graph of glucose concentration in the blood of Volunteer 1. Dots mark the values of the blood samples in the measurement process (used blood glucose meter Accu-Chek Active Roche). The average error in the measurement interval 150 minutes amounted to 6.8%.

Example 2. The processing of measurement results healthy Volunteers 2.

Male 45 years old, healthy, took the food load in the form of two cups of 200 grams of sweet drinks (Pepsi Cola). On Fig.2b shows graphs of the variation of the values of the impedance ZHFand ZLFand temperature T°C, taken from the sensor located on the forearm, and on Figa is a graph of glucose concentration in the blood of a Volunteer 2. Dots mark the values of the blood samples in the measurement process (used blood glucose meter Accu-Chek Active Roche). The average error in the measurement interval 140 minutes amounted to 7.2%.

Example 3. the processing of measurement results healthy Volunteers 3.

Male 42 years old, healthy, took a combined food load in the form of one banana and 200 g of sweet drinks (Pepsi Cola). On Fig.3b shows the changes of the values of the impedance ZHFand ZLFand temperature T°C, taken from the sensor located on the forearm, and on Figa is a graph of glucose concentration in the blood of the Volunteer 3. Dots mark the values of the blood samples in the measurement process (used blood glucose meter Accu-Chek Active Roche). The average error in the measurement interval 150 minutes amounted to 9.5%.

The tests showed that the proposed method can provide a smaller error in the determination of glucose concentration in human blood compared to known non-invasive methods.

1. The method of determining the concentration of glucose in the blood, characterized by the fact that consistently, at set intervals of time measured values of the impedance of the human body section at a high frequency and a low frequency using a fixed on the body and spaced from each other electrode,
on the basis of measured values of impedance at high frequency gain estimate of the volume of liquid contained in the tissues of the human body section between the electrodes,
on the basis of measured values of impedance low frequency gain estimate of the volume of the extracellular fluid, contained in the tissues of the human body section between the electrodes,
then define the increment value of the metabolic component of the above-mentioned volume of the extracellular fluid associated with the synthesis and utilization of energy in the human body, by determining the increment referred to estimates of the volume of liquid contained in the tissues of the human body section between the electrodes, compared with the previous measurement, determine the increment referred to estimating the volume of the extracellular fluid contained in the tissues of the human body section between the electrodes, compared with the previous measurement, and then calculating the difference between the increment estimates of the volume of liquid contained in the tissues of the human body section between the electrodes, and the above-mentioned increment estimates of the volume of extracellular fluid contained in the tissues of the human body section between the electrodes,
determine the increment value of glucose concentration in human blood by normalizing the above variables mentioned increment metabolic component of the volume of the extracellular fluid,
as the concentration of glucose in the blood is determined by summing the above variables increment of glucose concentration with a value of the concentration of glucose in the blood determined in the previous step measurements,
when the concentration of the glucose in the first time interval is determined by summing the above-mentioned increment of glucose concentration in human blood, obtained at the first time interval, the initial value of the glucose concentration.

2. The method according to claim 1, characterized in that the initial value of the concentration of glucose in the blood is determined in an alternative way, such as invasive.

3. The method according to claim 1, characterized in that the impedance measurement body part of a person is carried out using at least two electrodes.

4. The method according to claim 3, characterized in that the electrodes are set on the peripheral parts of the body, such as the hand or finger.

5. The method according to claim 1, characterized in that the impedance measurement body part of a person are with the time interval from 1 second to 10 minutes.



 

Same patents:

FIELD: medicine.

SUBSTANCE: claimed invention deals with methods for inducing an immune response to an antigen in a patient for treating human diseases by introduction of an immunogenic composition, where the said patient is selected from a population of patients of interest. In addition, the claimed invention deals with methods for determining whether the subject is or is not sensitive to development of a prophylactic or therapeutic immune response after such treatment.

EFFECT: increased efficiency of determination.

18 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: anamnestic and clinical data are collected: the presence of a symptom of deep venous thrombosis, immobilisation or surgical intervention for the preceding 4 weeks, with a history of thromboembolia of the pulmonary artery (TEPA), malignant growth, cardiovascular diseases, chronic obstructive pulmonary disease. A score is assigned for each sign. A patient's age and erythrocyte sedimentation rate are specified. A collection of the derived data is used to predict a risk of developing TEPA.

EFFECT: method enables providing more accurate prediction of TEPA at the early stage of the disease that is ensured by the complex assessment.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: there are involved visual examination and palpation; the primary and repeated examinations of the patient suffering haemangioma aim at measuring a haemangioma area, for round haemangiomas by formula S=(12×d)2×π, wherein S is the haemangioma area, cm2, d is a diameter of the round haemangioma, cm, π is pi character. For irregular figures, the calculation is approximate with using a squared off transparent film by applying the film of the haemangioma, and deriving the haemangioma area from a sum of the squares covering the haemangioma and square halves to produce two values: S2 the repeated area measurement, cm2, S1 the primary area measurement, cm2. A patient's body area is calculated by formula Sbody=body w./×height3600×10000, wherein body w. is body weight in kg, height is individual's height in cm to produce two values: Sbody2 is the repeated body surface area, cm2, Sbody1 is the primary body surface area, cm2. If the value is (S2S1S1Sbody2Sbody1Sbody1)×100exceeds10, the treatment is considered to be necessary.

EFFECT: method enables the objective and accurate determination of the indications for the beginning of treating the haemangioma by specifying the area and diameter of the haemangiomas.

1 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. Implementing the method implies the laser irradiation of an area of the maximum clustering of blood vessels. A back scattered radiation is received and instrumentally transformed by the recovery of a direction of a polarisation vector and an intensity. They are used to derive the blood glucose concentration. The back scattered radiation intensity and polarisation are recorded through two channels symmetrical to the laser beam. Receiving channel analysers are pre-adjusted at ±45° in relation to a transmission place of the polariser. That is combined with recording a blood microcirculation dynamics in the examined skin. The measurement is taken from the skin surface immediately. The device comprises an optical coherent emitter, a polariser, two analysers, two photodetectors recording the analyser light intensity, and a microlens. The device comprises a photodetector recording the blood microcirculation, a diaphragm with a microhole, amplifiers and an output processing unit.

EFFECT: group of inventions provides the more accurate measurement and creates a structure applicable as an individual mobile sensor carrier.

2 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: risk factors of the developing prothrombotic changes in the adolescents suffering essential arterial hypertension are determined, including: C677T gene polymorphism of 5,10-methylene tetrahydrofolate reductase; A66G gene polymorphism of methionine synthase reductase; an average daily diastolic blood pressure; an average night systolic blood pressure; a blood pressure load of daily systolic blood pressure; a burdened thrombotic genealogical history index; a family early thrombosis index. Assessing a combination of the determined risk factors enables stating a favourable prognosis and a low probability of the developing prothrombotic changes, or an unfavourable prognosis and a high probability of the developing prothrombotic changes.

EFFECT: method enables the high-accuracy prediction of the risk of the developing prothrombotic changes and detecting the thrombogenic risk in the adolescents suffering essential arterial hypertension.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at determining the manifestation of arthragra. A method involves determining the presence of tophi, a quantity of aggravations for a year, blood serum uric acid and calculating an index. The patient is additionally examined to determine signs of arthragra according to classification criteria presented in Table 1 included in the description to determine a quantity of the arthragra criteria and to calculate an index of the manifestation of arthragra by formula: IMA = the quantity of the arthragra + 3 × the presence of tophi + QAmonth + UAEF, wherein IMA is the index of the manifestation of arthragra; the presence of tophi: no tophi - 0, tophi - 1; QAmonth is the quantity of aggravations, months; UAEF is a blood serum uric acid excess factor.

EFFECT: method enables determining the manifestation of arthragra for the purpose of assessing the effectiveness of the therapy, dynamics of the patient's state for long-term prospective follow-up.

3 dwg, 5 tbl, 2 ex

FIELD: physics, control.

SUBSTANCE: invention relates to methods and systems for controlling electronic medical devices. The device control method involves bringing a plurality of medical devices into contact with the body of a patient, connecting the medical devices to communicate with a console via a digital interface, transmitting a message over the digital interface from the console, to be received simultaneously by the plurality of the medical devices and synchronising the medical devices with one another in response to the received message. The message is a source radio-frequency pulse; interfaces of the plurality of medical devices include a modem and a controller; receiving circuits of the modems are configured to detect source radio-frequency pulses before processing thereof by main circuits of the modems and signal to the controller when a radio-frequency pulse is detected, and the controller synchronises circuits of the medical devices. The method is carried out by a device which comprises a console, which is configured to transmit a message over a first digital interface simultaneously to multiple recipients, and a plurality of medical devices which are brought into contact with the body of a patient, having second digital interfaces configured to simultaneously receive the message transmitted by the console and to synchronise with one another in response to receiving the message.

EFFECT: use of the invention enables to synchronise operation of medical devices.

24 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely surgery, and can be used to evaluate and predict a risk of the haemorrhagic complications accompanying minimally invasive liver surgeries. The presence of the following signs (risk predictors) is scored pre- and intraoperatively in each person individually: evident or latent coagulopathy (CP), hepatic fibrosis or cirrhosis (HC), acute hepatic failure and/or evident cholestasis (CS), technical problems of the surgery (TP), a puncture canal diameter exceeding 1.6 mm (CD), multiple instrument passage through a parenchyma (IP), a dangerous location of a mass lesion (DL) and intra- and postoperative restlessness (R). A haemorrhagic complication risk index (HCRI) is calculated by formula HCRI=CP+HC+CS+TP+CD+IP+DL+R; the derived HCRI <4 points stands for a minimum risk; the HCRI falling within the range of 5-12 points shows a moderate risk, and the surgery is preceded by prescribing a haemostatic course; if the HCRI exceeds 12 points, a high risk of the complications is stated.

EFFECT: method enables more effective prediction of the haemorrhagic complications following the minimally invasive liver surgeries that is necessary for specifying further preventative options.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: surgical management of the heterotopic ossificates is preceded by analysing the patient's venous blood, and also describing and localising the ossificated by standardised X-ray imaging, multi-layer spiral CT and magnetic resonant tomography. Non-invasive laser Doppler flowmetry is used in a sitting or lying patient after a 30-minute rest with a sensor placed on the patient's skin in a projection of the heterotopic ossificates for 360-420 seconds at red laser light wavelength 0.63 mcm and probe volume 0.8-0.9 mm3 with applying spectral wavelet analysis of the blood flow oscillation to measure any sequences and to evaluate microhaemocirculation (perfusion units) of the soft tissues in a projection of the patient's heterotopic ossificates that describes general, i.e. capillary and extracapillary, average steady microvascular perfusion, and is proportional to an erythrocyte count and average linear rate in a probed volume; the range of spectral wavelet frequency oscillation amplitudes 0.0095-1.6 Hz is examined to specify and record the blood flow oscillation amplitudes of the proper myogenic origin within the frequency range of 0.07-0.145 Hz directly describing the nutritive passage of the examined tissues in a projection of the heterotopic ossificates. If the measured microhaemocirculation of the soft tissues in a projection of the heterotopic ossificates makes 0.5-1.8 perfusion units, the measured nutritive blood flow makes 0.3-1.0 perfusion units, while the wavelet spectrum of the blood flow oscillations within the frequency range of 0.07-0.145 Hz shows no myogenic oscillations, or the amplitude is negligible, then the processes of osteoid formation and mineralisation in a combination with formation and maturation of a spongy bone tissue of the new bone are stated to be completed, and an adequacy of the metabolic maturity of the patient's heterotopic ossificates is evidenced that testifies to advisability of the surgical management of the formed heterotopic ossificates. If the measured microhaemocirculation of the soft tissues in a projection of the heterotopic ossificates makes more than two perfusion units, the measured nutritive blood flow makes more than one perfusion unit, while the wavelet spectrum of the blood flow oscillations within the frequency range of 0.07-0.145 Hz shows predominant myogenic oscillations, the presence of active regenerative processes is stated that testifies to the fact that the processes of osteoid formation, mineralisation, as well as maturation of the spongy bone tissue of the new bone are incomplete that gives reasons to consider the surgical removal of the formed heterotopic ossificates to be premature.

EFFECT: method enables the objective assessment of the nature of the heterotopic ossification preceding the surgical management of the heterotopic ossificates.

3 ex

FIELD: medicine.

SUBSTANCE: endoscopic examination of the nasal cavity is performed. Inferior and middle concha mucosa of the nasal cavity is deslimed. A nasal mucosa fluorescence intensity is studies by an ultraviolet pulse laser on molecular nitrogen. At wave lengths 440 nm and 560 nm, spectral index F is derived from a logarithm of relation of a fluorescent intensity at minimum wave length (440 nm) to a fluorescent intensity at maximum wave length (560 nm). If the spectral index F is equal to 2.28±0.14, perennial allergic rhinitis is diagnosed. The spectral index F equal to 1.86±0.14 enables diagnosing seasonal allergic rhinitis.

EFFECT: technique enables fast and effective diagnosis of the form of allergic rhinitis.

3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Method applies control device, which contains measuring equipment and control unit. Method includes obtaining signal of skin conductivity, measured on the section of patient's skin within the interval of measurement, by means of measuring equipment. In accordance with the invention, by means of control unit calculated is characteristics of skin conductivity signal, representing static dispersion of values of skin conductivity signal throughout the interval of measurements, including calculation of standard deviation of values of skin conductivity signal throughout the interval of measurements. On the basis of said characteristics first outlet signal, indicating on patient's pain state or discomfort, is formed. Second signal, indicating state of patient's recovery, is formed on the basis of the same characteristics. Said control device is described.

EFFECT: increased accuracy of control over the state of autonomic nervous system.

13 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and may be used for assessing the functional state of organism. The method consists in stabilised current pulsing to a biological object, measuring a biological object voltage at the fixed point of time after the current pulse initiation and measuring a stabilised current I0. additionally Voltage fixing times represent t1 and t2, with t2=2t1. Biological object impedance components are an active impedance B and an equivalent capacitance C of biological object tissues that are calculated by formulas: R = E/I0, wherein E is a fixed potential with time constant T with wherein U1 and U2 are biological object voltage at the moments of time t1 and t2 respectively with C=T/R.

EFFECT: method provides higher accuracy and efficiency of the biological object complex impedance components by eliminating a systematic error and considering a dynamic accuracy taking place in the further similar invention.

4 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment. Device for measuring impedance of biological tissues contains successively connected matrix of N electrodes, commutation unit, instrument amplifier, detector unit, multi-channel ADC, microcontroller and PC. First and second digital-analogue converters, power amplifier and unit of current measurement are included into device. Commutation unit includes two analogue multiplexors and two analogue demultiplexors. N analogous inlets of each multiplexor are connected with respective N electrodes of electrode matrix, and N analogue outlets of each demultiplexor are connected with respective N electrodes of electrode matrix. Address inlets of either of two multiplexors and two demultiplexors are connected respectively with first four microcontroller outlets. First outlet of first multiplexor is connected with first inlet of instrument amplifier. Outlet of second multiplexor is connected with second inlet of instrument amplifier. Inlet of first demultiplexor is connected with first outlet of power amplifier. Inlet of second demultiplexor is connected with first outlet of current measurement unit.

EFFECT: application of the invention will make it possible to increase accuracy of measurement of electric conductivity of biotissues with change of probing current direction.

4 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to obstetrics. Method includes measurement of electric resistance. Active constituent of leg impedance is measured. Measurements are carried out by alternating current with frequency 4 kHz and intensity 10-4 A. Current is supplied to big toes. Drop of voltage is measured on little toes. For this purpose electrodes are applied on them in form of clip through gauze pads, soaked in hypertonic solution. In case if value of active impedance component is 68 Ohm and higher, conclusion about absence of edemas is made. In case if value of active impedance component is lower than 68 Ohm, conclusion about presence of edemas is made.

EFFECT: method is non-invasive, increases diagnostics accuracy and reduces time for its carrying out.

4 ex, 3 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology and can be used to determine progression of cancer of abdominal cavity organs. For this purpose dynamic examination of patient after surgical treatment is carried out. Change of patient's body composition is determined at the background of nutritive-metabolic therapy 1 time per not less often as 28-30 days by means of bioimpedance analysis. Body weight, index of body weight, fat mass, as well as mass of extracellular liquid are assessed. If body weight, index of body weight decrease and/or fat mass decreases with simultaneous increase of extracellular liquid mass in comparison with the previous results of bioimpedance analysis, progression of cancer of abdominal cavity organs in patient is determined.

EFFECT: method ensures 100% accuracy of early determination of tumour progression in patients before X-ray manifestation, which provides possibility of earlier start of chemo-radiotherapy and prolong patient's life span.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology. Method includes measurement of electric impedance of chest by bipolar method. Measurements are carried out at frequency of probing alternating electric current, not lower than 100 kHz. For this purpose electrodes are applied on both halves of chest on parasternal lines at the level of III-IV intercostals spaces. Average values of module impedance |Z| and phase angle |φ| are registered for 1-5 minutes. After that, coefficient |Z||φ| is calculated. If coefficient increases more than 5 times, chronic heart failure is diagnosed.

EFFECT: method ensures increase of early diagnostics accuracy.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine. In method realisation active and passive electrodes are installed on the surface of biological tissue. Source of electric energy is switched to them. After that, impact on tissue by two pulses with electric power of specified value following one another is performed on them. Impulse of specified power of larger value follows impulse of specified power of smaller value. Electric parameters of biological tissue, corresponding to each value of specified power, are measured and their ratio is used to estimate electrophysiological state of biological tissue.

EFFECT: invention makes it possible to increase self-descriptiveness and objectivity of method of measuring electric parameters of biological tissue with simplification of realisation of method techniques.

2 cl, 1 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy, diagnostics. Method includes analysis of electric parameters before and after treatment. Measurement of skin electric potentials is carried out. Electric potentials are measured in corporal biologically active points (BAP). BAP of the first group are selected from points, located directly in the area of knee joint, such as Zu-San-Li, Du-Bi, Liang-Qui, Yin-Ling-Quan, Yang-Ling-Quan, Xi-Yang-Guan. BAP of the second group are selected from points, located outside knee joint, but on meridians, passing through knee joint, such as Yong-Quan, Xing-Quan, Da-Dun, Qu-Quan, Shu-Fu. Selection of not fewer than 3 from each group is carried out. If average indices of electric potentials, measured in BAP after treatment, are higher relative to indices, measured in BAP before treatment by 25% and higher, it testifies about achievement of treatment effect.

EFFECT: method is objective, simple in implementation, safe for patient.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to diagnostics. Method includes introduction of needle electrodes with active current-conducting end into tumour. After that their advance into tumour depth is performed. As they move, indices of bioimpedance (BIM) are measured five times at current frequency 2 kHz and voltage 1.02 V. If BIM indices decrease in the period of advance of electrodes into tumour depth, tumour is benign. If BIM indices vary, or grow, tumour is malignant.

EFFECT: method reduces tome of examination, is simple in implementation.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, therapy, dietetics and can be applied for correction and prevention of obesity. Estimation of indices of body weight (IWB), food status (FS), factual nutrition (FN) and food behavior (FB) is carried out. If patient has disturbed FS, FN and FB, than psychotherapist and dietitian carry out individual (IS) or group sessions (GS) of FB and FN correction with them for ten days, then, 1 time/week for a month. If FS and FN are disturbed, IS and GS are carried out for five days, after that, GS is carried out daily for a month. If FB is disturbed, psychotherapist carries out IS for correction of FB for five days, then, daily GS for month. In case of any combination of FC, FN, FB disturbance: if IWB equals 27-29.9, medication dietressa is administered in dose 1 pill 4 times/day for 3 months. If by FN estimation real daily caloricity of dietary intake (RDC DI) is higher than calculated by 200% and more, gradual reduction of daily calorage is administered: for the first week not more than 15% from initial, for the second - not more than 30%, for the third - not more than 50%, for the fourth - not more than 75% from initial, for the fifth and the following weeks - daily calorage corresponds to individual calculated caloricity of dietary intake with account of power consumption. If RDC DI is higher than calculated by from 199% to 101% reduction of daily calorage is administered: for the first week not more than 20% from initial, for the second - not more than 40%, for the third - not more than 70% from initial, for the fourth and the following - daily calorage corresponds to calculated individual caloricity with account of power consumption. If by data of bio-impedometry content of total water (CTW) in organism is more than 50% higher than consumption of liquid is not more than 1.5 l/day. If CTW reduction is more than 50%, consumption of liquid is not less than 2.5 l/day. If CTW change is 50% and less, consumption of liquid must constitute 2 l/day.

EFFECT: method ensures stable effect of body weight correction, with individualisation of food status, food behavior, factual nutrition, increase of patients' life quality.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves carrying out urological examination for determining hydrodynamic resistance of ureter calculated from formula Z=8Lμ/(πR4), where Z is the hydrodynamic resistance of ureter, L is the ureter length, R is the ureter radius, μ is the urine viscosity. Angle α at which the ureter enters the urinary bladder is determined from formula cosα = 8l1μ/(ZπR4), where l1 is the perpendicular drawn from the upper edge of the ureter to the its exit projection line, μ is the urine viscosity, Z is the hydrodynamic resistance of ureter, R is the ureter radius. Vesicoureteral reflux recidivation is predicted when the angle of α+90° is less than 120°.

EFFECT: enhanced effectiveness in reducing the number of recidivation cases.

2 dwg, 1 tbl

Up!